BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23015379)

  • 1. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation.
    Jarvis JN; Govender N; Chiller T; Park BJ; Longley N; Meintjes G; Bekker LG; Wood R; Lawn SD; Harrison TS
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(6):374-9. PubMed ID: 23015379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
    Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
    PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.
    Longley N; Jarvis JN; Meintjes G; Boulle A; Cross A; Kelly N; Govender NP; Bekker LG; Wood R; Harrison TS
    Clin Infect Dis; 2016 Mar; 62(5):581-587. PubMed ID: 26565007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
    Govender NP; Roy M; Mendes JF; Zulu TG; Chiller TM; Karstaedt AS
    HIV Med; 2015 Sep; 16(8):468-76. PubMed ID: 25689352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptococcal meningitis: a review of cryptococcal antigen screening programs in Africa.
    Greene G; Lawrence DS; Jordan A; Chiller T; Jarvis JN
    Expert Rev Anti Infect Ther; 2021 Feb; 19(2):233-244. PubMed ID: 32567406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.
    Liechty CA; Solberg P; Were W; Ekwaru JP; Ransom RL; Weidle PJ; Downing R; Coutinho A; Mermin J
    Trop Med Int Health; 2007 Aug; 12(8):929-35. PubMed ID: 17697087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.
    Ramachandran A; Manabe Y; Rajasingham R; Shah M
    BMC Infect Dis; 2017 Mar; 17(1):225. PubMed ID: 28335769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing deaths from cryptococcal meningitis: from bench to bedside.
    Roy M; Chiller T
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):715-7. PubMed ID: 21905781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
    Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
    Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.
    Lofgren S; Abassi M; Rhein J; Boulware DR
    Expert Rev Anti Infect Ther; 2017 Apr; 15(4):331-340. PubMed ID: 28111998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
    Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
    Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
    Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
    BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Cryptococcal Antigen Screening and Evolution of Asymptomatic Cryptococcal Antigenemia among HIV-Infected Women Starting Antiretroviral Therapy in Thailand.
    Kwan CK; Leelawiwat W; Intalapaporn P; Anekthananon T; Raengsakulrach B; Peters PJ; McNicholl JM; Park BJ; McConnell MS; Weidle PJ
    J Int Assoc Provid AIDS Care; 2014; 13(5):434-7. PubMed ID: 24003059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
    Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa.
    Vallabhaneni S; Longley N; Smith M; Smith R; Osler M; Kelly N; Cross A; Boulle A; Meintjes G; Govender NP
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):e37-e42. PubMed ID: 26926942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.
    Jarvis JN; Harrison TS; Lawn SD; Meintjes G; Wood R; Cleary S
    PLoS One; 2013; 8(7):e69288. PubMed ID: 23894442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis.
    Chen J; Zhang R; Shen Y; Liu L; Qi T; Wang Z; Mehraj V; Routy JP; Lu H
    HIV Med; 2019 Jan; 20(1):69-73. PubMed ID: 30311440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.
    Wake RM; Britz E; Sriruttan C; Rukasha I; Omar T; Spencer DC; Nel JS; Mashamaite S; Adelekan A; Chiller TM; Jarvis JN; Harrison TS; Govender NP
    Clin Infect Dis; 2018 Feb; 66(5):686-692. PubMed ID: 29028998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptococcal immune reconstitution inflammatory syndrome.
    Longley N; Harrison TS; Jarvis JN
    Curr Opin Infect Dis; 2013 Feb; 26(1):26-34. PubMed ID: 23242412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.